Comparing the current results to its competitors, Zentalis Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 25.03 %, recorded in the same quarter.
Zentalis Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 206.93 %
Zentalis Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company faces potential competition from major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Competitors may possess greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may consolidate resources among fewer competitors. Smaller or early-stage companies may also present significant competition, particularly through collaborations with larger firms. Competitors also vie for qualified personnel, clinical trial site establishment, patient registration, and acquisition of complementary technologies. The company's commercial opportunities may be diminished or eliminated if competitors develop medicines that are safer, more effective, more convenient, or less expensive.
October 13, 2025
: Zentalis Pharmaceuticals has showcased significant advancements in the development of their novel therapeutic, azenosertib. Recent data presentations at major conferences, including the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the Society of Gynecologic Oncology Annual Meeting, reveal promising results in the treatment of cancers such as platinum-resistant ovarian cancer (PROC). The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for azenosertib in Cyclin E1 positive patients, further substantiating its potential in targeted cancer therapies. The continuous evolution of targeted cancer therapies has marked a significant milestone i...
September 16, 2024
In a significant development for the biopharmaceutical industry, Zentalis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on their investigational cancer therapy, azenosertib. Additionally, the company is on track to present pivotal data from key clinical studies in the fourth quarter of 2024. This news marks a crucial step forward for Zentalis and could have far-reaching implications for both the company and patients eagerly awaiting new therapeutic options. The Lifting of the Partial Hold Earlier in their clinical program, Zentalis Pharmaceuticals had encountered regulatory hurdles when the FDA imposed a partial clinical hold on their stud...
September 9, 2024
: Zentalis Pharmaceuticals has made significant advancements in cancer treatment methodology through the preclinical evaluation of Azenosertib, a potent drug candidate exhibiting synergistic effects when paired with topoisomerase I (TOP1) inhibitor-based antibody-drug conjugates (ADCs). This article synthesizes findings presented by Zentalis to underscore Azenosertib s potential in enhancing anti-tumor efficacy and its implications for future clinical applications.Recent developments in cancer therapeutics have increasingly focused on combining different modalities to enhance efficacy and reduce resistance. Antibody-drug conjugates (ADCs) represent a novel approach by directly targeting tumor cells while del...
June 18, 2024
Update on the Clinical Development Program of Azenosertib by Zentalis Pharmaceuticals The clinical development of Azenosertib, a novel therapeutic agent developed by Zentalis Pharmaceuticals, has encountered significant regulatory obstacles. The U.S. Food and Drug Administration (FDA) has imposed a partial clinical hold on the ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib. This article provides a comprehensive overview of the current status, implications, and future directions for the clinical development of Azenosertib. Azenosertib (also known as ZN-c3) is an investigational drug being developed by Zentalis Pharmaceuticals. It is a selective inhibitor of WEE1, a protein kinase involved ...
Publicly Traded Peers of Zentalis Pharmaceuticals Inc
Zymeworks Inc Share Performance
-10.46%
30 Days
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Zentalis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zentalis Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
